Canada markets close in 18 minutes
  • S&P/TSX

    19,066.55
    -156.19 (-0.81%)
     
  • S&P 500

    3,815.47
    -6.08 (-0.16%)
     
  • DOW

    31,005.29
    +58.30 (+0.19%)
     
  • CAD/USD

    0.7757
    -0.0012 (-0.15%)
     
  • CRUDE OIL

    109.53
    -2.23 (-2.00%)
     
  • BTC-CAD

    25,922.06
    -421.30 (-1.60%)
     
  • CMC Crypto 200

    433.44
    -6.23 (-1.42%)
     
  • GOLD FUTURES

    1,820.40
    -0.80 (-0.04%)
     
  • RUSSELL 2000

    1,716.72
    -22.12 (-1.27%)
     
  • 10-Yr Bond

    3.0930
    -0.1130 (-3.52%)
     
  • NASDAQ

    11,161.06
    -20.48 (-0.18%)
     
  • VOLATILITY

    27.94
    -0.42 (-1.48%)
     
  • FTSE

    7,312.32
    -11.09 (-0.15%)
     
  • NIKKEI 225

    26,804.60
    -244.87 (-0.91%)
     
  • CAD/EUR

    0.7425
    +0.0089 (+1.21%)
     

Syros to Report First Quarter 2022 Financial Results on Monday, May 16, 2022

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass., May 09, 2022--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Monday, May 16, 2022 to report its first quarter 2022 financial results and provide a corporate update.

To access the live conference call, please dial (866) 595-4538 (domestic) or (636) 812-6496 (international) and refer to conference ID 4664097. A webcast of the call will also be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

About Syros Pharmaceuticals

Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: tamibarotene, a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors and blood cancers. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220509005028/en/

Contacts

Media:
Courtney Solberg
Syros Pharmaceuticals
917-698-9253
csolberg@syros.com

Investor:
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting